pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,408 catalysts · 7,021 phase readout · 2,430 8k filing · 386 earnings · 3 pdufa · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: earnings×type: adcom×clear all
type
  • phase readout7,021
  • 8k filing2,430
  • earnings386
  • pdufa3
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›RECRUITINGphase readoutNCT06160791: Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Sponsor: Jerry Lee, MD, MSc, MPhil. Phase: PHASE2. Conditions: Hemophagocytic Lymphohistiocytoses

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07162350: Food as Medicine Study

Sponsor: Parkland Health and Hospital System. Phase: NA. Conditions: Chronic Diseases in Children

full page →ctgov ↗
›RECRUITINGphase readoutNCT06966791: Sexual Functıon in Young Women After Breast Cancer Surgery

Sponsor: ATİYE KAŞ ÖZDEMİR. Phase: . Conditions: Breast Cancer Surgery, Young Adult Females

full page →ctgov ↗
›COMPLETEDphase readoutNCT06628791: BK329 and Body Fat Reduction

Sponsor: Pusan National University Yangsan Hospital. Phase: NA. Conditions: Obesity and Overweight

full page →ctgov ↗
›RECRUITINGphase readoutNCT07360418: Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.

Sponsor: Applied Biologics, LLC. Phase: . Conditions: Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic, Ulcer, Diabetic Foot Ulcer

full page →ctgov ↗
›COMPLETEDphase readoutNCT05677997: Evaluating the Impact of Resource Navigators to Support LTC and RH Staff During and Beyond COVID-19

Sponsor: Unity Health Toronto. Phase: NA. Conditions: Wellness, Burnout, Caregiver, Burnout, Professional, COVID-19, Vaccine Refusal

full page →ctgov ↗
›RECRUITINGphase readoutNCT07578610: Biomedical Signal Extraction From Symptom Descriptions: An Observational Registry Using the OpenGenome Platform

Sponsor: OpenGenome. Phase: . Conditions: Signs and Symptoms, Fever, Myalgia, Skin Diseases, Hemorrhagic Fever With Renal Syndrome, Zoonoses

full page →ctgov ↗
›RECRUITINGphase readoutNCT03854110: A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

Sponsor: Persevere Therapeutics Inc.. Phase: PHASE1. Conditions: Ovarian Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT03395210: A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Sponsor: Principia Biopharma, a Sanofi Company. Phase: PHASE2. Conditions: Immune Thrombocytopenia

full page →ctgov ↗
›RECRUITINGphase readoutNCT06689410: Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms

Sponsor: Nantes University Hospital. Phase: NA. Conditions: Aneurysm, Brain Aneurysm, Congenital Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT05696613: A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Sponsor: Cerium Pharmaceuticals, Inc.. Phase: PHASE3. Conditions: Primary Membranous Nephropathy

full page →ctgov ↗
›RECRUITINGphase readoutNCT06570213: Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD

Sponsor: Rush University Medical Center. Phase: EARLY_PHASE1. Conditions: PTSD

full page →ctgov ↗
›COMPLETEDphase readoutNCT05651360: Diagnostic Performance of Low-Dose CT for Acute Abdominal Conditions

Sponsor: Oslo University Hospital. Phase: . Conditions: Abdominal Pain, Acute Pain, Acute Cholecystitis, Acute Appendicitis, Acute Pancreatitis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07391020: Text Message Safety Behavior Fading for Pathological Worry

Sponsor: Florida State University. Phase: NA. Conditions: Generalized Anxiety Disorder (GAD), Worrying, Anxiety

full page →ctgov ↗
›COMPLETEDphase readoutNCT06695130: Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Sponsor: Sanofi. Phase: PHASE1. Conditions: COVID-19 Immunization, Influenza Immunization

full page →ctgov ↗
›RECRUITINGphase readoutNCT05777330: Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes

Sponsor: Universitair Ziekenhuis Brussel. Phase: NA. Conditions: Type1 Diabetes Mellitus

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05035030: Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Sponsor: Albireo, an Ipsen Company. Phase: PHASE3. Conditions: Alagille Syndrome

full page →ctgov ↗
›RECRUITINGphase readoutNCT07742228: SCENAR Therapy in Chronic Non-specific Neck Pain

Sponsor: Hopital Foch. Phase: NA. Conditions: Cervicalgia, Neck Pain, Chronic Pain

full page →ctgov ↗
›RECRUITINGphase readoutNCT03958565: Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Sponsor: University of Colorado, Denver. Phase: . Conditions: Carcinoma, Non-Small-Cell Lung

full page →ctgov ↗
›RECRUITINGphase readoutNCT06214065: Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)

Sponsor: Yale University. Phase: NA. Conditions: Autism Spectrum Disorder

full page →ctgov ↗
›RECRUITINGphase readoutNCT06951867: Tezspire Cardiac Events PASS

Sponsor: AstraZeneca. Phase: . Conditions: Cardiovascular Events, MACE

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03319667: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Sponsor: Sanofi. Phase: PHASE3. Conditions: Plasma Cell Myeloma

full page →ctgov ↗
›COMPLETEDphase readoutNCT05961267: Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism

Sponsor: University Hospital, Bordeaux. Phase: . Conditions: Arthritis, Rheumatoid, Spondylitis, Ankylosing, Lupus Erythematosus, Systemic, Scleroderma, Systemic, Sjogren's Syndrome, Mixed Connective Tissue Disease

full page →ctgov ↗
›COMPLETEDphase readoutNCT06680167: Hyperbaric Prilocaine 2% vs Hyperbaric Bupivacaine 0.5% in Caesarean Section

Sponsor: Sohag University. Phase: EARLY_PHASE1. Conditions: Spinal Anesthesia

full page →ctgov ↗
›COMPLETEDphase readoutNCT06164600: Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children

Sponsor: Ain Shams University. Phase: PHASE2. Conditions: Urinary Tract Infections, Recurrent, Child, Prevention & Control, Infections, Urologic Diseases, Communicable Diseases

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT00590200: GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Disease

Sponsor: The Cleveland Clinic. Phase: . Conditions: Cardiovascular Diseases

full page →ctgov ↗
›RECRUITINGphase readoutNCT07281300: Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer

Sponsor: The Hong Kong Polytechnic University. Phase: NA. Conditions: Symptom Cluster, Breathlessness, Coughing, Fatigue Symptom, Lung Cancer Patients, Brain Activity

full page →ctgov ↗
›RECRUITINGphase readoutNCT06371300: Photobiomodulation With REd vs BluE Light (REBEL)

Sponsor: Aston University. Phase: NA. Conditions: Dry Eye Syndromes, Meibomian Gland Dysfunction, Blepharitis

full page →ctgov ↗
›COMPLETEDphase readoutNCT04997200: Effect of Sleep Deprivation on Breathlessness and Exercise Capacity in COPD

Sponsor: Skane University Hospital. Phase: NA. Conditions: COPD

full page →ctgov ↗
›TERMINATEDphase readoutNCT06021600: A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07457307: Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac

Sponsor: NYU Langone Health. Phase: PHASE1. Conditions: High-grade Glioma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07014592: Characterization and Analysis of Evoked Cortical Responses in Participants With Medication-intractable Epilepsy

Sponsor: University of Michigan. Phase: NA. Conditions: Intractable Epilepsy

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07187336: The Efficacy and Safety of Shoulder Motion Style Acupuncture Treatment (MSAT) on in Patients With Shoulder Pain Caused by Traffic Accidents

Sponsor: Jaseng Medical Foundation. Phase: NA. Conditions: Shoulder Pain

full page →ctgov ↗
›COMPLETEDphase readoutNCT07467811: Single-Blind, Investigational Device Exemption Paired-Design, Non-Inferiority Trial With Confirmation for the Assessment of the Efficacy and Safety of a Universal Electrosurgical Device for Temporary Improvement of Mild and Moderate Wrinkles Around Both Eye Corners and Both Cheek Folds

Sponsor: TENTECH INC.. Phase: NA. Conditions: Wrinkles

full page →ctgov ↗
›RECRUITINGphase readoutNCT07691411: An Ecological Momentary Assessment Based Program to Support Self-Management for Post-stroke Patients

Sponsor: The Hong Kong Polytechnic University. Phase: NA. Conditions: Stroke, Post Stroke

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06161571: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Sponsor: Akero Therapeutics, Inc. Phase: PHASE3. Conditions: NASH/MASH, NAFLD/MASLD

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07607444: CBT-I in Physically Active Participants With Insomnia Complaints

Sponsor: Federal University of Jatai. Phase: NA. Conditions: Insomnia

full page →ctgov ↗
›COMPLETEDphase readoutNCT05801809: Understanding the Effects of Transauricular Vagus Nerve Stimulation on Neural Networks and Autonomic Nervous System

Sponsor: Spaulding Rehabilitation Hospital. Phase: NA. Conditions: Healthy Volunteers

full page →ctgov ↗
›RECRUITINGphase readoutNCT07341009: Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease

Sponsor: University Hospital, Caen. Phase: . Conditions: Alzheimer's Disease (AD), Time Perception

full page →ctgov ↗
›RECRUITINGphase readoutNCT06246799: Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Sponsor: The University of Texas Health Science Center at San Antonio. Phase: PHASE3. Conditions: Type 2 Diabetes (Adult Onset)

full page →ctgov ↗
›RECRUITINGphase readoutNCT06948799: A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects

Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd. Phase: PHASE1. Conditions: Oligozoospermia

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT01808599: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Sponsor: International Extranodal Lymphoma Study Group (IELSG). Phase: PHASE2. Conditions: MALT Lymphoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07322432: The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction

Sponsor: VapeAway. Phase: PHASE2. Conditions: Addiction Nicotine

full page →ctgov ↗
›COMPLETEDphase readoutNCT04167163: Abaloparatide Before Total Knee Arthroplasty

Sponsor: University of Wisconsin, Madison. Phase: PHASE4. Conditions: Osteoporosis, Arthroplasties, Knee Replacement

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT02960087: Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

Sponsor: Canadian Cancer Trials Group. Phase: NA. Conditions: Prostate Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07690787: JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

Sponsor: Chinese University of Hong Kong. Phase: PHASE2. Conditions: Recurrent/ Metastatic NPC

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06917287: A Clinical Study to Evaluate the Efficacy of Native CT-II® in Individuals With Knee Osteoarthritis

Sponsor: Vedic Lifesciences Pvt. Ltd.. Phase: NA. Conditions: Knee Osteoarthritis (OA)

full page →ctgov ↗
›COMPLETEDphase readoutNCT07373093: Predictors of Measles Vaccine Hesitancy in New York State

Sponsor: Albany Medical College. Phase: . Conditions: Measles Vaccination

full page →ctgov ↗
›RECRUITINGphase readoutNCT07535593: Transcutaneous Electrical Acupoint Stimulation at Jing-Well Points for Disorders of Consciousness

Sponsor: Xijing Hospital. Phase: PHASE2. Conditions: Disorders of Consciousness Due to Severe Brain Injury

full page →ctgov ↗
›COMPLETEDphase readoutNCT07505693: The Effect of Health Belief Model-Based Education on Knowledge and Behavioral Changes Regarding Dementia in Older Adults

Sponsor: Hasan Kalyoncu University. Phase: NA. Conditions: Aged 60 Years or Older, Volunteering to Participate in the Study, Dementia Education, Prevention Intervention

full page →ctgov ↗
← prev
page 147 of 149
next →